FisclearFisclear
Sign in
Annual ReportHealthcare

Chugai Pharmaceutical Co., Ltd.

4519.T · Period ending 2025-12-31 · Filed 2025-12-31 · Updated

In short

Chugai Pharmaceutical Co., Ltd. (4519.T) has net income up 12.1% to JPY 434.0B and EPS (Diluted) up 12.0% to JPY 263.72 year on year. Its net margin is 34.5% and gross margin 71.1%, and it trades at 21.0× trailing earnings. Fisclear flags 1 medium-severity risk and no high-severity ones. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

¥6,019

Market Cap

¥9.90T

P/E (TTM)

21.0x

Price ÷ earnings per share

P/B

4.9x

Price ÷ book value

P/S (TTM)

7.4x

Price ÷ revenue per share

EV / EBITDA

13.2x

Beta

0.56

Moderate market correlation

Dividend Yield

2.19%

PEG Ratio

1.5x

P/E ÷ earnings growth rate

52-Week Range

¥5,974¥6,019 now¥10,700

4-engine score — Quality and Peers engines require SEC EDGAR (US stocks only)

Efficiency
72/100
Value
45/100
Cashflow
60/100
Regime
55/100

Operating margin 47.6% — high profitability.

Based on filing period ending Dec 2025

International FisclearScore uses 4 engines (no EDGAR data). Based on Yahoo Finance & Alpha Vantage reported financials. Not financial advice.

4519.T vs

🇯🇵 Japan Macro Indicators

Full dashboard →

Policy Rate

0.30%→

Accommodative

10-Year Yield

2.94%→

Spread: +2.6%

USD/JPY

157.81→

The Japan central bank policy rate stands at 0.30% — an accommodative rate environment; the 10-year government bond yield is 2.94%; USD/JPY is at 157.81.

SWOT Analysis — 4519.T

Inflationary Boom
Macro lens (Inflationary Boom): Rising costs and tighter margins amplify financial risks in this regime.
✦

Strengths

  • Net Income: JPY 434.0B (+12.1% YoY) — Profit grew 12% — the company kept more of each dollar earned.

  • EPS (Diluted): JPY 263.72 (+12.0% YoY) — Earnings per share rose 12% — each share earned more.

  • Total Assets: JPY 2.5T (+11.8% YoY) — Total assets grew 12% — the company's resource base expanded.

  • Gross Profit: JPY 894.3B (+7.6% YoY) — Gross profit rose 8% — the spread between revenue and direct costs improved.

◈

Weaknesses

  • Operating Cash Flow: JPY 386.3B (-13.7% YoY) — Operating cash flow fell 14% but remained positive.

◎

Opportunities

No clear opportunities identified at this time.

⚠

Threats

  • Stock is within 10% of its 52-week low (5974.00) — the market may be pricing in significant risk or sector weakness.

Financial Charts

Revenue vs Net Income

Gross Profit vs Operating Income

Margin Trend

Year-over-Year Changes

Operating Cash Flow

JPY 386.3B

was JPY 447.6B

−13.7%

Operating cash flow fell 14% but remained positive.

Net Income

JPY 434.0B

was JPY 387.3B

+12.1%

Profit grew 12% — the company kept more of each dollar earned.

EPS (Diluted)

JPY 263.72

was JPY 235.36

+12.0%

Earnings per share rose 12% — each share earned more.

Total Assets

JPY 2.5T

was JPY 2.2T

+11.8%

Total assets grew 12% — the company's resource base expanded.

Gross Profit

JPY 894.3B

was JPY 831.2B

+7.6%

Gross profit rose 8% — the spread between revenue and direct costs improved.

Risk Flags

0 high · 1 medium · 0 low
  • ◈ Medium

    Stock is within 10% of its 52-week low (5974.00) — the market may be pricing in significant risk or sector weakness.

Price HistoryJPY

Technical Signals

Daily closes · 1-year data

Latest News

via Finnhub

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Research Chugai Pharmaceutical Co., Ltd.

SEC EDGAR ↗Yahoo Finance ↗Google Finance ↗

Data sourced from Tokyo Stock Exchange, FRED (Federal Reserve), OECD, BIS, and Yahoo Finance. For informational purposes only. Not financial advice.